menu
    • menu

    Company profile for Lysogene

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LYSOGENE was founded in 2009, by Karen Aiach and Olivier Danos, with a focused scientific development plan, pragmatic approach and bold mission. The company has been built on a comprehensive understanding of the impact of neurodegenerative diseases on patients and families.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LysogeneFrance Flag
    Country
    Country
    France
    Address
    Address
    18-20 rue Jacques Dulud 92 200 Neuilly-sur-Seine
    Telephone
    Telephone
    + 33 1 41 43 03 90
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lysogene.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lysogene
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/LYSOGENE

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lysogene Announces the Extension of Deadline for the Submission of Offers
    Lysogene Announces the Extension of Deadline for the Submission of Offers

    16 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230216005627/en

    BUSINESSWIRE
    16 Feb 2023
    Share Share
    Lysogene: Conversion of Safeguard Proceedings Into Reorganization Proceedings
    Lysogene: Conversion of Safeguard Proceedings Into Reorganization Proceedings

    25 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230124006101/en

    BUSINESSWIRE
    25 Jan 2023
    Share Share
    Lysogene: Launch of a Process to Find Buyers or Investors and Request
    Lysogene: Launch of a Process to Find Buyers or Investors and Request

    06 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230106005167/en

    BUSINESSWIRE
    06 Jan 2023
    Share Share
    A former Sarepta partner asks French courts to oversee restructuring
    A former Sarepta partner asks French courts to oversee restructuring

    08 Dec 2022

    // Max Gelman ENDPTS

    https://endpts.com/nearly-out-of-cash-a-former-sarepta-partner-asks-french-courts-to-oversee-restructuring/

    Max Gelman ENDPTS
    08 Dec 2022
    Share Share
    Lysogene looks for saving grace after trial flop
    Lysogene looks for saving grace after trial flop

    07 Dec 2022

    // FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/lysogene-looking-saving-grace-after-trial-flop-suspends-stock-trading-and-seeks

    FIERCEBIOTECH
    07 Dec 2022
    Share Share
    Lysogene Provides Updates Results from Phase 2/3 AAVance Gene Therapy Study
    Lysogene Provides Updates Results from Phase 2/3 AAVance Gene Therapy Study

    29 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221129005837/en

    BUSINESSWIRE
    29 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search